Edition:
United Kingdom

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

90.95EUR
13 Sep 2019
Change (% chg)

€-0.45 (-0.49%)
Prev Close
€91.40
Open
€89.40
Day's High
€91.10
Day's Low
€87.95
Volume
195,643
Avg. Vol
130,025
52-wk High
€153.95
52-wk Low
€86.05

Latest Key Developments (Source: Significant Developments)

Ipsen Sees 2019 Group Sales Growth Greater Than 14%
Thursday, 25 Jul 2019 

July 25 (Reuters) - Ipsen SA ::IPSEN DELIVERS STRONG RESULTS FOR THE FIRST HALF OF 2019 WITH ROBUST DOUBLE-DIGIT SALES GROWTH AND IMPROVED CORE OPERATING MARGIN AND UPGRADES ITS GUIDANCE FOR FULL YEAR 2019.H1 OPERATING INCOME EUR 317.8 MILLION VERSUS EUR 269.7 MILLION YEAR AGO.GROUP SALES GROWTH GREATER THAN +14.0% AT CONSTANT CURRENCY AND CONSOLIDATION SCOPE.UPGRADED FULL YEAR 2019 GUIDANCE.H1 GROUP SALES NET EUR 1.23 BILLION VERSUS EUR 1.06 BILLION YEAR AGO.H1 CORE OPERATING MARGIN AT 31.5% OF NET SALES, UP 1.2 POINTS AND CORE OPERATING INCOME GROWTH OF 20.1% AFTER HIGHER RESEARCH AND DEVELOPMENT INVESTMENTS INCLUDING CLEMENTIA.FOR FY 2019 SEES GROUP SALES GROWTH GREATER THAN +14.0% AT CONSTANT CURRENCY AND CONSOLIDATION SCOPE (VERSUS INITIAL GUIDANCE OF GREATER THAN +13.0%).H1 CONSOLIDATED NET PROFIT EUR 220.6 MILLION VERSUS EUR 197.3 MILLION YEAR AGO.SEES 2019 CORE OPERATING MARGIN AT AROUND 30.0% OF NET SALES.  Full Article

Ipsen And Servier Announce Initial Phase 1/2 Clinical Data
Friday, 5 Jul 2019 

July 5 (Reuters) - IPSEN SA ::AND SERVIER ANNOUNCE INITIAL PHASE 1/2 CLINICAL DATA EVALUATING LIPOSOMAL IRINOTECAN (ONIVYDE).APPROXIMATELY THREE QUARTERS OF PATIENTS (71.9%) ACHIEVED DISEASE CONTROL AT WEEK 16, WHILE 34% HAD A RESPONSE (SECONDARY ENDPOINT).71.9% (23/32) OF STUDY PATIENTS IN THE 50/60 PP ACHIEVED DISEASE CONTROL AT 16 WEEKS.TREATMENT EMERGENT ADVERSE EVENTS GRADE 3 OR HIGHER WERE REPORTED BY 20 OF 32 PATIENTS FROM THE 50/60 DOSE POOLED PATIENT ANALYSIS; NO PATIENT REPORTED GRADE 3 OR HIGHER FATIGUE OR PERIPHERAL NEUROPATHY (PRIMARY ENDPOINT).  Full Article

Ipsen Announces FDA Approval For Pre-Filled Syringe For Somatuline Depot
Monday, 24 Jun 2019 

June 24 (Reuters) - Ipsen SA ::IPSEN ANNOUNCES U.S. FDA APPROVAL FOR NEWLY DESIGNED PRE-FILLED SYRINGE FOR SOMATULINE® DEPOT (LANREOTIDE).IPSEN BIOPHARMACEUTICALS - HEALTHCARE PROVIDERS CAN EXPECT TO RECEIVE NEW SYRINGE DURING Q3 2019.  Full Article

Exelixis And Ipsen Initiate Phase 3 Pivotal Trial Of Cabozantinib
Wednesday, 5 Dec 2018 

Dec 5 (Reuters) - IPSEN SA ::EXELIXIS AND IPSEN INITIATE PHASE 3 PIVOTAL TRIAL (COSMIC-312) OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB VERSUS SORAFENIB IN PREVIOUSLY UNTREATED ADVANCED HEPATOCELLULAR CARCINOMA.  Full Article

Exelixis' Partner Ipsen Receives European Commission Approval Of Cabometyx Tablets
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - Exelixis Inc ::EXELIXIS’ PARTNER IPSEN RECEIVES EUROPEAN COMMISSION APPROVAL FOR CABOMETYX® (CABOZANTINIB) TABLETS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN ADULTS PREVIOUSLY TREATED WITH SORAFENIB.UNDER TERMS OF COLLABORATION AGREEMENT WITH IPSEN, EXELIXIS WILL RECEIVE A MILESTONE PAYMENT OF $40 MILLION FOR EUROPEAN COMMISSION APPROVAL.PAYMENT WILL BE PAID BY IPSEN WITHIN NEXT 70 DAYS.  Full Article

Ipsen European Commission Approves Cabometyx For Treatment Of Hepatocellular Carcinoma In Adults
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - IPSEN SA ::EUROPEAN COMMISSION APPROVES IPSEN’S CABOMETYX® (CABOZANTINIB) FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN ADULTS PREVIOUSLY TREATED WITH SORAFENIB.APPROVAL ALLOWS FOR MARKETING OF CABOMETYX(®) (CABOZANTINIB) IN THIS INDICATION IN ALL 28 MEMBER STATES OF EUROPEAN UNION, NORWAY AND ICELAND.EC APPROVAL IS BASED ON RESULTS OF GLOBAL PLACEBO-CONTROLLED CELESTIAL PHASE 3 PIVOTAL TRIAL WHICH MET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL.  Full Article

Ipsen Q1 Sales up at 510.3 Million Euros
Thursday, 26 Apr 2018 

April 26 (Reuters) - IPSEN SA ::IPSEN REPORTS STRONG Q1 2018 SALES GROWTH OF 23.1% AT CONSTANT EXCHANGE RATES.Q1 GROUP SALES GROWTH OF 23.1%.FULL YEAR 2018 GUIDANCE CONFIRMED.Q1 SALES EUR 510.3 MILLION VERSUS EUR 438.0 MILLION YEAR AGO.  Full Article

Ipsen Announces EMA Validation Of Filing Of New Application For Additional Indication For Cabometyx®
Wednesday, 28 Mar 2018 

March 28 (Reuters) - IPSEN SA ::ANNOUNCES EMA VALIDATION OF FILING OF A NEW APPLICATION FOR ADDITIONAL INDICATION FOR CABOMETYX®, FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC).‍FILING BASED ON GLOBAL PLACEBO-CONTROLLED PHASE 3 TRIAL RESULTS WHICH MET PRIMARY ENDPOINT OF OVERALL SURVIVAL​.  Full Article

Ipsen Announces Health Canada Approval Of Dysport Therapeutic For Treatment Of Lower Limb Spasticity In Adults
Thursday, 15 Mar 2018 

March 15 (Reuters) - Ipsen Sa ::IPSEN ANNOUNCES HEALTH CANADA APPROVAL OF DYSPORT THERAPEUTIC (ABOBOTULINUMTOXINA) FOR THE TREATMENT OF LOWER LIMB SPASTICITY IN ADULTS.IPSEN SA - HEALTH CANADA APPROVED DYSPORT THERAPEUTIC FOR SYMPTOMATIC TREATMENT OF FOCAL SPASTICITY AFFECTING LOWER LIMBS IN ADULTS.  Full Article

Ipsen FY IFRS Operating Income Up At 397.2 Million Euros
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - IPSEN SA ::IPSEN DELIVERS STRONG 2017 RESULTS WITH 21.1%1 SALES GROWTH AND CORE OPERATING MARGIN INCREASE OF 3.4 POINTS AND EXPECTS SIGNIFICANT FURTHER GROWTH IN SALES AND MARGIN IN 2018.‍FULL YEAR 2017 GROUP SALES GROWTH OF 21.1%​.‍FULL YEAR 2017 CORE OPERATING MARGIN AT 26.4%, UP 3.4 POINTS​.‍FINANCIAL GUIDANCE FOR 2018 OF GROUP SALES GROWTH GREATER THAN 16.0%​.‍FINANCIAL GUIDANCE FOR 2018 CORE OPERATING MARGIN GREATER THAN 28.0% OF NET SALES​.FY IFRS OPERATING INCOME EUR 397.2‍​ MILLION VERSUS EUR 304.7 MILLION YEAR AGO.FY IFRS CONSOLIDATED NET PROFIT EUR 272.9‍​ MILLION VERSUS EUR 226.6 MILLION YEAR AGO.FY GROUP SALES EUR 1.91‍​ BILLION VERSUS EUR 1.58 BILLION UR AGO.FY FREE CASH FLOW EUR ‍​309.0 MILLION VERSUS EUR 228.8 MILLION YEAR AGO.  Full Article

French and Benelux stocks-Factors to watch

May 14 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.